Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-Aza-2'- deoxycytidine

NeuroImmunoModulation

Volumn 19, Issue 3, 2012, Pages 180-186

  Börner, Christine ^a   Martella, Elisa ^a   Höllt, Volker ^a   Kraus, Jürgen ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

5 Aza 2' deoxycytidine; Cannabinoid; Epigenetics; Opioid; Receptor; Trichostatin A

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BETA ACTIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLIC AMP; MESSENGER RNA; MORPHINE; MU OPIATE RECEPTOR; TRICHOSTATIN A;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NEUROBLASTOMA CELL; NEUROMODULATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; EPIGENESIS, GENETIC; HUMANS; HYDROXAMIC ACIDS; JURKAT CELLS; NEUROBLASTOMA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, OPIOID, MU; T-LYMPHOCYTES;

EID: 84855882349     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000331474     Document Type: Article

References (40)

1. Kieffer BL, Gaveriaux-Ruff C: Exploring the opioid system by gene knockout. Prog Neurobiol 2002; 66: 285-306. (Pubitemid 34518287)
2. Wang J, Barke RA, Charboneau R, Loh HH, Roy S: Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways. J Biol Chem 2003; 278: 37622-37631. (Pubitemid 37175285)
3. Sacerdote P, Manfredi B, Gaspani L, Panerai AE: The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in BALB/cJ mice. Blood 2000; 95: 2031-2036. (Pubitemid 30151642)
4. Wang J, Barke RA, Roy S: Transcriptional and epigenetic regulation of interleukin-2 gene in activated T cells by morphine. J Biol Chem 2007; 282: 7164-7171. (Pubitemid 47093680)
5. Borner C, Warnick B, Smida M, Hartig R, Lindquist JA, Schraven B, Hollt V, Kraus J: Mechanisms of opioid-mediated inhibition of human T cell receptor signaling. J Immunol 2009; 183: 882-889.
6. Mansour A, Fox CA, Akil H, Watson SJ: Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 1995; 18: 22-29.
7. Kraus J, Borner C, Giannini E, Hickfang K, Braun H, Mayer P, Hoehe MR, Ambrosch A, Konig W, Hollt V: Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J Biol Chem 2001; 276: 43901-43908.
8. Borner C, Woltje M, Hollt V, Kraus J: STAT6 transcription factor binding sites with mismatches within the canonical 5′-TTC... GAA-3′ motif involved in regulation of delta-and mu-opioid receptors. J Neurochem 2004; 91: 1493-1500.
9. Borner C, Hollt V, Kraus J: Cannabinoid receptor type 2 agonists induce transcription of the μ-opioid receptor gene in Jurkat T cells. Mol Pharmacol 2006; 69: 1486-1491.
10. Borner C, Stumm R, Hollt V, Kraus J: Comparative analysis of mu-opioid receptor expression in immune and neuronal cells. J Neuroimmunol 2007; 188: 56-63. (Pubitemid 47095015)
11. Kraus J, Lehmann L, Borner C, Hollt V: Epigenetic mechanisms involved in the induction of the mu opioid receptor gene in Jurkat T cells in response to interleukin-4. Mol Immunol 2010; 48: 257-263.
12. Kraus J, Borner C, Giannini E, Hollt V: The role of nuclear factor kappaB in tumor necrosis factor-regulated of the human micro-opioid receptor gene. Mol Pharmacol 2003; 64: 876-884. (Pubitemid 37153056)
13. Borner C, Kraus J, Bedini A, Schraven B, Hollt V: T cell receptor/CD28-mediated activation of human T lymphocytes induces expression of functional micro-opioid receptors. Mol Pharmacol 2008; 74: 496-504.
14. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD: Medicinal use of cannabis in the USA: historical perspectives, current trends, and future directions. J Opioid Manag 2009; 5: 153-168.
15. Klein TW, Newton C, Larsen K, Chou J, Perkins I, Lu L, Nong L, Friedman H: Cannabinoid receptors and T helper cells. J Neuroimmunol 2004; 147: 91-94. (Pubitemid 38114954)
16. Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, Roth MD: Delta 9-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 2002; 133: 124-131. (Pubitemid 35346734)
17. Ihenetu K, Molleman A, Parsons M, Whelan C: Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells. Eur J Pharmacol 2003; 464: 207-215. (Pubitemid 36293741)
18. Borner C, Smida M, Hollt V, Schraven B, Kraus J: Cannabinoid receptor type 1-and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J Biol Chem 2009; 284: 35450-35460.
19. Brown AJ: Novel cannabinoid receptors. Br J Pharmacol 2007; 152: 567-575. (Pubitemid 350041541)
20. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202. (Pubitemid 34575709)
21. Borner C, Hollt V, Sebald W, Kraus J: Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. J Leukoc Biol 2007; 81: 336-343. (Pubitemid 46021284)
22. Borner C, Bedini A, Hollt V, Kraus J: Analysis of promoter regions regulating basal and interleukin-4-inducible expression of the human CB1 receptor gene in T lymphocytes. Mol Pharmacol 2008; 73: 1013-1019. (Pubitemid 351397906)
23. Borner C, Hollt V, Kraus J: Activation of human T cells induces upregulation of cannabinoid receptor type 1 transcription. Neuroimmunomodulation 2007; 14: 281-286. (Pubitemid 351737854)
24. Rossi B, Zenaro E, Angiari S, Ottoboni L, Bach S, Piccio L, Pietronigro EC, Scarpini E, Fusco M, Leon A, Constantin G: Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase Adependent mechanism. J Neuroimmunol 2011; 233: 97-105.
25. Berger SL: The complex language of chromatin regulation during transcription. Nature 2007; 447: 407-412. (Pubitemid 46816746)
26. Jenuwein T, Allis CD: Translating the histone code. Science 2001; 293: 1074-1080. (Pubitemid 32758077)
27. Wolffe AP, Matzke MA: Epigenetics: regulation through repression. Science 1999; 286: 481-486.
28. Luckow B, Schutz G: CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements. Nucleic Acids Res 1987; 15: 5490.
29. Borner C, Hollt V, Kraus J: Involvement of activator protein-1 in transcriptional regulation of the human mu-opioid receptor gene. Mol Pharmacol 2002; 61: 800-805. (Pubitemid 34273160)
30. Horton JK, Martin RC, Kalinka S, Cushing A, Kitcher JP, O'Sullivan MJ, Baxendale PM: Enzyme immunoassays for the estimation of adenosine 3′ ,5′ cyclic monophosphate and guanosine 3′ ,5′ cyclic monophosphate in biological fluids. J Immunol Methods 1992; 155: 31-40.
31. Karpf AR, Jones DA: Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002; 21: 5496-5503. (Pubitemid 34983484)
32. Jones PA: DNA methylation and cancer. Cancer Res 1986; 46: 461-466. (Pubitemid 16145385)
33. Tsankova N, Renthal W, Kumar A, Nestler EJ: Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8: 355-367. (Pubitemid 46652469)
34. Urdinguio RG, Sanchez-Mut JV, Esteller M: Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 2009; 8: 1056-1072.
35. Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Borner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, Diaz-Hernandez M, Ruiz C, Sendtner M, Lucas JJ, de Yebenes JG, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Gines S, Kraus J, Fernandez-Ruiz J, Galve-Roperh I, Guzman M: Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2011; 134: 119-136.
36. Allen KL, Waldvogel HJ, Glass M, Faull RL: Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. J Chem Neuroanat 2009; 37: 266-281.
37. Lastres-Becker I, Berrendero F, Lucas JJ, Martin-Aparicio E, Yamamoto A, Ramos JA, Fernandez-Ruiz JJ: Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res 2002; 929: 236-242. (Pubitemid 34178339)
38. Kraus J: Regulation of mu-opioid receptors by cytokines. Front Biosci (Schol Ed) 2009; 1: 164-170.
39. Xu Y, Carr LG: Binding of Sp1/Sp3 to the proximal promoter of the hMOR gene is enhanced by DAMGO. Gene 2001; 274: 119-128. (Pubitemid 32817129)
40. Hwang CK, Kim CS, Kim do K, Law PY, Wei LN, Loh HH: Up-regulation of the mu-opioid receptor gene is mediated through chromatin remodeling and transcriptional factors in differentiated neuronal cells. Mol Pharmacol 2010; 78: 58-68.